Dr Reddy’s Labs Share Price Target: Dr Reddy’s Laboratories, a Hyderabad-headquartered pharmaceutical company, on Wednesday, July 23, announced its financial results for the first quarter of FY26. The company posted a net profit of Rs 1,410 crore, marking a one per cent increase over the corresponding period a year ago.
The drug maker’s revenue increased to Rs 8,545 crore during the period from Rs 7,673 crore a year ago.
Here is how analysts and experts are reading the pharma firm’s latest earnings report.
How to trade Dr Reddy’s stock now?
Zee Business Managing Editor Anil Singhvi has recommended buying Dr Reddy’s Labs futures for targets of Rs 1,265, Rs 1,275, and Rs 1,282 with a stop loss at Rs 1,231.
Analysts at brokerages Goldman Sachs, JPMorgan, Jefferies, CLSA, Morgan Stanley, Citi, and HSBC have mixed views on the drug maker.
Goldman Sachs has maintained a ‘neutral’ rating on Dr Reddy’s Labs shares, raising its target for the stock to Rs 1,200 from Rs 1,175.
JPMorgan has maintained an ‘underweight’ rating with a target of Rs 1,090, revised from Rs 1,060.
Jefferies has maintained an ‘underperform’ rating on the stock, with an increased target price of Rs 1,100 instead of the earlier Rs 1,010.
Meanwhile, Morgan Stanley has maintained an ‘equal-weight’ rating on Dr Reddy’s shares with a target of Rs 1,298. According to the brokerage, approval for semaglutide–the active ingredient in blockbuster drugs like Ozempic and Wegovy, used for type 2 diabetes and weight loss–will come between October and November 2025, with a launch scheduled for January 2026.
Citi has maintained a ‘sell’ call on Dr Reddy’s shares with a target price of Rs 990.
HSBC has a ‘buy’ call on the stock with a target of Rs 1,400.
